Patents by Inventor Marta Nevalainen

Marta Nevalainen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10899753
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: January 26, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Jürgen Schulz, Marta Nevalainen, Michael Dechantsreiter
  • Publication number: 20190382394
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: May 13, 2019
    Publication date: December 19, 2019
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Jürgen Schulz, Marta Nevalainen, Michael Dechantsreiter
  • Publication number: 20170119734
    Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof, wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Application
    Filed: April 22, 2016
    Publication date: May 4, 2017
    Inventors: Adilah Bahadoor, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • Patent number: 9346769
    Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: May 24, 2016
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Adilah Bahadoor, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • Publication number: 20140079667
    Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Application
    Filed: August 23, 2013
    Publication date: March 20, 2014
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Adilah BAHADOOR, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • Patent number: 8609706
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: December 17, 2013
    Assignee: Infinity Discovery, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence Blas Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • Patent number: 8546432
    Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: October 1, 2013
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Adilah Bahadoor, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • Publication number: 20130243727
    Abstract: Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Application
    Filed: April 29, 2013
    Publication date: September 19, 2013
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Adilah BAHADOOR, Alfredo C. CASTRO, Lawrence K. CHAN, Gregg F. KEANEY, Marta NEVALAINEN, Vesa NEVALAINEN, Stephane PELUSO, Thomas T. TIBBITTS
  • Patent number: 8450350
    Abstract: Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: May 28, 2013
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Adilah Bahadoor, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Thomas T. Tibbitts
  • Publication number: 20130131063
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Application
    Filed: May 15, 2012
    Publication date: May 23, 2013
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence Blas Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • Patent number: 8236956
    Abstract: The present invention provides compositions and methods for modulating smoothened-dependent pathway activation. The present invention provides analogs of cyclopamine that can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, Ptc loss-of-function or smoothened gain-of-function mutations. The compounds of the present invention are particularly useful in treating cancers.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: August 7, 2012
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Alfredo C. Castro, Michael A. Foley, Somarajan Nair Janardanan Nair, Marta Nevalainen, James R. Porter, Martin R. Tremblay
  • Patent number: 8178690
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: May 15, 2012
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence Blas Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • Publication number: 20110274655
    Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Application
    Filed: May 5, 2011
    Publication date: November 10, 2011
    Applicant: Infinity Pharmaceuticals
    Inventors: Adilah BAHADOOR, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • Publication number: 20110274654
    Abstract: Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Application
    Filed: May 5, 2011
    Publication date: November 10, 2011
    Inventors: Adilah BAHADOOR, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Thomas T. Tibbitts
  • Publication number: 20110213145
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Application
    Filed: April 19, 2011
    Publication date: September 1, 2011
    Applicant: Infinity Discovery, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence B. Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • Publication number: 20110166353
    Abstract: The present invention provides compositions and methods for modulating smoothened-dependent pathway activation. The present invention provides analogs of cyclopamine that can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, Ptc loss-of-function or smoothened gain-of-function mutations. The compounds of the present invention are particularly useful in treating cancers.
    Type: Application
    Filed: December 15, 2010
    Publication date: July 7, 2011
    Inventors: Julian Adams, Alfredo C. Castro, Michael A. Foley, Somarajan Nair Janardanan Nair, Marta Nevalainen, James R. Porter, Martin R. Tremblay
  • Patent number: 7928244
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: April 19, 2011
    Assignee: Infinity Discovery, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence B. Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • Patent number: 7875628
    Abstract: The present invention provides compositions and methods for modulating smoothened-dependent pathway activation. The present invention provides analogs of cyclopamine that can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, Ptc loss-of-function or smoothened gain-of-function mutations. The compounds of the present invention are particularly useful in treating cancers.
    Type: Grant
    Filed: July 10, 2008
    Date of Patent: January 25, 2011
    Assignee: Infinity Discovery, Inc.
    Inventors: Julian Adams, Alfredo C. Castro, Michael A. Foley, Somarajannair Janardanannair, Marta Nevalainen, James R. Porter, Martin R. Tremblay
  • Publication number: 20080269272
    Abstract: The present invention provides compositions and methods for modulating smoothened-dependent pathway activation. The present invention provides analogs of cyclopamine that can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, Ptc loss-of-function or smoothened gain-of-function mutations. The compounds of the present invention are particularly useful in treating cancers.
    Type: Application
    Filed: July 10, 2008
    Publication date: October 30, 2008
    Inventors: Julian Adams, Alfredo C. Castro, Michael A. Foley, Somarajan Nair Janardanan Nair, Marta Nevalainen, James R. Porter, Martin R. Tremblay
  • Patent number: 7407967
    Abstract: The present invention provides compositions and methods for modulating smoothened-dependent pathway activation. The present invention provides analogs of cyclopamine that can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, Ptc loss-of-function or smoothened gain-of-function mutations. The compounds of the present invention are particularly useful in treating cancers.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: August 5, 2008
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Alfredo C. Castro, Michael A. Foley, Somarajan Nair Janardanan Nair, Marta Nevalainen, James R. Porter, Martin R. Tremblay